Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 290

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

Open access
Weller, M., Gorlia, T., Cairncross, J.G., van den Bent, M.J., Mason, W., Belanger, K., Brandes, A.A., Bogdahn, U., Macdonald, D.R., Forsyth, P., Rossetti, A.O., Lacombe, D., Mirimanoff, R.-O., Vecht, C.J., Stupp, R.·2011·Neurology

Abstract

OBJECTIVE: This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma. METHODS: The European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) CE.3 clinical trial database of radiotherapy (RT) with or without temozolomide (TMZ) for newly diagnosed glioblastoma was examined to assess the impact of the interaction between AED use and chemoradiotherapy on survival. Data were adjusted for known prognostic factors. RESULTS: When treatment began, 175 patients (30.5%) were AED-free, 277 (48.3%) were taking any enzyme-inducing AED (EIAED) and 135 (23.4%) were taking any non-EIAED. Patients receiving valproic acid (VPA) only had more grade 3/4 thrombopenia and leukopenia than patients without an AED or patients taking an EIAED only. The overall survival (OS) of patients who were receiving an AED at baseline vs not receiving any AED was similar. Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93). CONCLUSIONS: VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e31822f02e1

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 290

Metadata

Authors
Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., Rossetti, A. O., Lacombe, D., Mirimanoff, R.-O., Vecht, C. J., & Stupp, R.
Venue
Neurology
Published
2011-09-20
Volume
77
Issue
12
Pages
1156-1164
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2091956563
Cited by
290
References
18
FWCI
14.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. https://app.cochat.ai/papers/10.1212/wnl.0b013e31822f02e1
The paper
Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., Rossetti, A. O., Lacombe, D., Mirimanoff, R.-O., Vecht, C. J., & Stupp, R. (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. https://doi.org/10.1212/wnl.0b013e31822f02e1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.